Citigroup Inc Affimed N.V. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.32 - $0.62 $641 - $1,243	-2,005 Reduced 94.26%	122 $0
Q3 2023 Nov 09, 2023	SELL	$0.46 - $0.65 $717 - $1,013	-1,559 Reduced 42.3%	2,127 $1,000
Q2 2023 Aug 10, 2023	BUY	$0.57 - $1.08 $1,075 - $2,036	1,886 Added 104.78%	3,686 $2,000
Q1 2023 May 11, 2023	SELL	$0.66 - $1.29 $806 - $1,576	-1,222 Reduced 40.44%	1,800 $1,000
Q4 2022 Feb 09, 2023	SELL	$1.1 - $2.45 $1,144 - $2,548	-1,040 Reduced 25.6%	3,022 $3,000
Q3 2022 Nov 10, 2022	SELL	$1.96 - $3.32 $15,384 - $26,058	-7,849 Reduced 65.9%	4,062 $8,000
Q2 2022 Aug 10, 2022	BUY	$2.27 - $4.86 $9,170 - $19,634	4,040 Added 51.33%	11,911 $33,000
Q1 2022 May 12, 2022	SELL	$3.69 - $5.65 $93,301 - $142,860	-25,285 Reduced 76.26%	7,871 $34,000
Q4 2021 Feb 10, 2022	BUY	$5.37 - $7.07 $74,449 - $98,018	13,864 Added 71.86%	33,156 $183,000
Q3 2021 Nov 10, 2021	BUY	$5.54 - $7.51 $106,877 - $144,882	19,292 New	19,292 $119,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.